< Back to the Blog

About the author

Dr Mary Parman
Dr. Mary Parman is an OB/GYN with nearly 20 years of experience and a leading voice at the intersection of clinical care and women’s health technology.

Sources

  1. North American Menopause Society. (2022). The 2022 hormone therapy position statement. Menopause, 29(7), 767-794.
  2. Santoro, N., et al. (2023). Menopausal hormone therapy for primary prevention: Why the USPSTF is wrong. Menopause, 30(6), 579-586.
  3. Stuenkel, C.A., et al. (2015). Treatment of symptoms of the menopause: An Endocrine Society clinical practice guideline. Journal of Clinical Endocrinology & Metabolism, 100(11), 3975-4011.
  4. Santen, R.J., et al. (2010). Postmenopausal hormone therapy: An Endocrine Society scientific statement. Journal of Clinical Endocrinology & Metabolism, 95(7 Supplement 1), s1-s66.
  5. Files, J.A., et al. (2011). Bioidentical hormone therapy. Mayo Clinic Proceedings, 86(7), 673-680.
  6. Simon, J.A., et al. (2006). Effective testosterone therapy in women: Dosing, levels and monitoring. Maturitas, 53(1), 35-40.
  7. Kingsberg, S.A., et al. (2023). Patient-reported outcomes and HRT optimization. Climacteric, 26(3), 234-241.
  8. The NAMS 2017 Hormone Therapy Position Statement Advisory Panel. (2017). The 2017 hormone therapy position statement of The North American Menopause Society. Menopause, 24(7), 728-753.

About the Oova Blog:
Our content is developed with a commitment to high editorial standards and reliability. We prioritize referencing reputable sources and sharing where our insights come from. The Oova Blog is intended for informational purposes only and is never a substitute for professional medical advice. Always consult a healthcare provider before making any health decisions.